School of Allied Health, University of Western Australia, Perth, Western Australia, Australia.
Medical School, University of Western Australia, Perth, Western Australia, Australia.
Intern Med J. 2020 Aug;50(8):944-950. doi: 10.1111/imj.14437.
Few studies have examined complementary medicine (CM) use in diabetes. Australian data are inconsistent, limited in scope and have not considered cost.
To evaluate the prevalence, associates and costs of CM in a contemporary Australian urban, community-based cohort of people with type 2 diabetes.
Baseline CM use was determined as part of a detailed assessment in 1543 of 1551 Fremantle Diabetes Study Phase II (FDS2) participants with type 2 diabetes (mean age 65.7 years, 51.8% males, median diabetes duration 9.0 years) recruited to the FDS2 between 2008 and 2011 who self-reported medication use including CM defined as non-prescription medicinal products.
A total of 672 FDS2 type 2 participants (43.6%) used at least one type of CM, 92% of which were nutritional supplements (omega-3 fatty acids/fish oil in 24% of CM users followed by calcium in 11%, glucosamine in 10% and others in <10%). Independent associates of CM use included older age, female sex, any mobility problem, and, inversely, Southern European or Indigenous Australian background, lack of English fluency, ex/current smoking status, taking oral glucose-lowering medications and higher HbA . The total annual estimated cost of CM used by FDS2 participants with type 2 diabetes was A$121 640 or A$79 ± 208 per person (range A$0-2993). Extrapolating these data, the 1 million Australians with type 2 diabetes spend A$79 million/year on CM.
CM use in type 2 diabetes is both common and costly. Healthcare professionals should consider discussing safe and cost-effective use of CM with their patients with type 2 diabetes.
鲜有研究调查过糖尿病患者对补充医学（CM）的使用情况。澳大利亚的数据存在出入，范围有限，且未考虑成本因素。
评估当代澳大利亚城市社区 2 型糖尿病患者中 CM 的流行情况、相关因素和费用。
在 2008 年至 2011 年期间招募的 1551 名 Fremantle Diabetes Study Phase II（FDS2）参与者中，有 1543 名参与者接受了详细评估，其中包括基线 CM 使用情况。FDS2 参与者中有 2 型糖尿病（平均年龄 65.7 岁，51.8%为男性，中位糖尿病病程 9.0 年），并自我报告了药物使用情况，包括定义为非处方药品的 CM。
FDS2 中共有 672 名 2 型参与者（43.6%）使用了至少一种类型的 CM，其中 92%为营养补充剂（CM 使用者中有 24%使用ω-3 脂肪酸/鱼油，其次是 11%的钙、10%的葡萄糖胺和其他<10%的产品）。CM 使用的独立相关因素包括年龄较大、女性、任何行动问题，以及相反地，具有南欧或澳大利亚原住民背景、英语不流利、曾经/现在吸烟、服用口服降血糖药物和更高的 HbA 水平。FDS2 2 型糖尿病患者使用 CM 的年总成本估计为 121640 澳元，或每人 79 澳元（208 澳元±208 澳元，范围 0-2993 澳元）。根据这些数据推断，100 万澳大利亚 2 型糖尿病患者每年在 CM 上花费 7900 万澳元。
2 型糖尿病患者对 CM 的使用既常见又昂贵。医疗保健专业人员应考虑与 2 型糖尿病患者讨论 CM 的安全和经济有效的使用。
